VCM
CRBP icon

Versant Capital Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Versant Capital Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.64K Hold
601
– – ﹤0.01% 2411
2026
Q1 		$5.64K Hold
601
– – ﹤0.01% 2344
2025
Q4 		$4.89K Hold
601
– – ﹤0.01% 2260
2025
Q3 		$7.6K Hold
601
– – ﹤0.01% 2049
2025
Q2 		$4.15K Buy
+601
New +$4.37K ﹤0.01% 2217

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Versant Capital Management's CRBP Position: Q2 2026 in Review

Versant Capital Management held its Corbus Pharmaceuticals (CRBP) position steady in Q2 2026 at 601 shares worth $5.64K. The position accounts for ﹤0.01% of the portfolio, ranked #2411.

Versant Capital Management first reported a position in CRBP in Q2 2025 and has held it in 5 quarters since. The position peaked at $7.6K in Q3 2025. 107 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.

  • Versant Capital Management held 601 shares of Corbus Pharmaceuticals worth $5.64K as of Q2 2026.
  • Versant Capital Management left its Corbus Pharmaceuticals share count unchanged in Q2 2026.
  • Corbus Pharmaceuticals made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #2411 holding.
  • Versant Capital Management first reported a position in Corbus Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Versant Capital Management's Corbus Pharmaceuticals position peaked at $7.6K in Q3 2025.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.